Abstract
Aim: In this study, we tested the hypothesis that lipid peroxide-derived dicarboxylic acids, by virtue of their ability bind to calcium, might be involved in atherosclerotic calcification. We determined the ability of azelaic acid (AzA) to promote calcification in human aortic smooth muscle cells (HASMC), identified AzA in human calcified atherosclerotic lesions, and compared its levels with control and non-calcified atherosclerotic lesions. Results: HASMCs efficiently converted 9-oxononanoic acid (ONA), a lipid peroxide derived monocarboxylic aldehyde, to AzA. In vitro incubations of AzA micelles with HASMC resulted in the formation of calcium deposits which contained AzA. LC-MS analysis of human control uninvolved artery, non-calcified, and calcified lesions showed significant increase of AzA in calcified lesions compared to non-calcified and control tissues. Calcified mouse atherosclerotic lesions also showed substantial presence of AzA in calcium complexes. Innovation: This study identifies a dicarboxylic acid, AzA, as an integral part of the calcium complex. The study also demonstrates the conversion of a lipid peroxidation product, ONA as a potential source of AzA, and establishes the presence of AzA in calcified materials isolated from human and mouse lesions. Conclusion: The presence of AzA as a calcium sequestering agent in atherosclerotic lesions might indicate, a) participation of oxidized-LDL (Ox-LDL) derived products in calcification, b) explain the potential correlation between calcification and overall plaque burden (as Ox-LDL has been suggested to be involved in atherogenesis), c) could contribute to plaque stabilization via its anti-inflammatory actions, and d) might explain why antioxidants failed to affect atherosclerosis in clinical studies.

This publication has 58 references indexed in Scilit: